Extensive circumferential partial-thickness sclerectomy in eyes with extreme nanophthalmos and spontaneous uveal effusion. Issue 12 (15th March 2019)

• Record Type: Journal Article
• Authors: Mansour, Ahmad; Stewart, Michael W; Shields, Carol L; Hamam, Rola; Abdul Fattah, Maamoun; Sheheitli, Huda; Mehanna, Carl-Joe; Yassine, Salma; Chahine, Hasan; Keaik, Mona; Maalouf, Fadi; Jaroudi, Mahmoud
• Is Part Of: British journal of ophthalmology. Volume 103:Issue 12(2019)
• Page Start: 1862
• Page End: 1867
• Publication Date: 2019-03-15
• Subjects: sclera and episclera -- retina -- macula -- uveal effusion -- nanophthalmos; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2018-313702
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Aim: To describe an extensive scleral excision technique to treat uveal effusion in nanophthalmic eyes. Methods: This prospective, interventional series of eight eyes of five consecutive patients with nanophthalmos underwent scleral window surgeries. Ninety per cent of the scleral thickness, extending from immediately behind the extraocular muscle insertions to the vortex veins for 3 and 1/4 quadrants, was removed. The main outcome measure was resolution of the uveal effusions. Results: Eight eyes of five patients (one female and four male) with a mean age of 46 years were studied. The mean (range) axial length was 16.1 mm (14.6–17.6 mm), and the mean refractive error was +13.6 dioptres (+10.75 to +16.00 dioptres). Following scleral excision surgery, all uveal effusions resolved within an average (±SD) of 13.9 (±8.7) days. The uveal effusion recurred in only one eye that had a vasoproliferative retinal tumour. The mean best corrected visual acuity improved from 0.69 logarithm of the minimum angle of resolution (logMAR) (Snellen equivalent: 20/97) at baseline to 0.51 logMAR (Snellen equivalent: 20/64; Wilcoxon paired t-test: p=0.016) after a mean follow-up of 35.6 months. Conclusion: The circumferential scleral window technique produces rapid resolution of uveal effusion in nanophthalmic eyes. No adverse effects were noted after surgery and the clinical effect was durable through 1 year. Trial registration number: NCT03748732 .